Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25820020 | 0.80 | ALDH1A1 (0.37) | ALDH1A1LMNATHRBALOX15MAPK1 | |
| SCHEMBL19984445 | 0.77 | ALDH1A1 (0.34) | ALDH1A1LMNATHRBALOX15MAPK1 | |
| SCHEMBL25820125 | 0.77 | ALOX15 (0.41) | ALDH1A1LMNATHRBALOX15MAPK1 | |
| SCHEMBL18789463 | 0.74 | ALDH1A1 (0.36) | ALDH1A1LMNATHRBALOX15MAPK1 | |
| SCHEMBL26022084 | 0.71 | ALDH1A1 (0.38) | ALDH1A1LMNATHRBALOX15MAPK1 | |
| SCHEMBL25819931 | 0.71 | ALDH1A1 (0.38) | ALDH1A1LMNATHRBALOX15MAPK1 | |
| SCHEMBL15095714 | 0.69 | ALDH1A1 (0.35) | ALDH1A1LMNATHRBALOX15MAPK1 | |
| SCHEMBL24245791 | 0.68 | ALOX15 (0.57) | ALDH1A1LMNATHRBALOX15MAPK1 | |
| SCHEMBL22892039 | 0.68 | ALOX15 (0.57) | ALDH1A1LMNATHRBALOX15MAPK1 | |
| SCHEMBL24245779 | 0.68 | ALOX15 (0.57) | ALDH1A1LMNATHRBALOX15MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11066625-B2 | Blends containing enantiomerically pure Ambrocenide® | SYMRISE AG (DE) | 2021-07-20 | — | — | US | disclosed |
| US-20200172830-A1 | BLENDS CONTAINING ENANTIOMERICALLY PURE AMBROCENIDE® | SYMRISE AG (DE) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172830-A1 | BLENDS CONTAINING ENANTIOMERICALLY PURE AMBROCENIDE® | OR51E2, CYP1B1, QDPR | ALDH1A1 431/4885LMNA 3423/4885THRB 2491/4885 |
| US-11066625-B2 | Blends containing enantiomerically pure Ambrocenide® | OR51E2, CYP1B1, QDPR | ALDH1A1 431/4885LMNA 3423/4885THRB 2491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.